Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology

Abstract

Meta-analysis based upon individual participant data (IPD) is a powerful methodology for synthesizing evidence by combining information drawn from multiple trials. Hitherto, its principal application has been in questions of clinical management, but an increasingly important use is in clarifying trials methodology, for instance in the selection of endpoints, as discussed in this review. In oncology, the Aide et Recherche en Cancérologie Digestive (ARCAD) Metastatic Colorectal Cancer Database is a leader in the use of IPD-based meta-analysis in methodological research. The ARCAD database contains IPD from over 38,000 patients enrolled in 46 studies and continues to collect Phase III trial data. Here, we review the principal findings of the ARCAD project in respect of endpoint selection and examine their implications for cancer trials. Analysis of the database has confirmed that progression-free survival (PFS) is no longer a valid surrogate endpoint predictive of overall survival in the first-line treatment of colorectal cancer. Nonetheless, PFS remains an endpoint of choice for most first-line trials in metastatic colorectal cancer and other solid tumors. Only substantial PFS effects are likely to translate into clinically meaningful benefits, and accordingly we advocate an oncology research model designed to identify highly effective treatments in carefully defined patient groups. We also review the use of the ARCAD database in assessing clinical response including novel response metrics, and prognostic markers. These studies demonstrate the value of IPD as a tool for methodological studies and provide a reference point for the expansion of this approach within clinical cancer research.

Geriatric impairments are prevalent and predictive of survival in older patients with cancer receiving radiotherapy: a prospective observational study

“…These outcomes are based on measures of tumour growth and also referred to as tumour-centred endpoints. These include overall response rate (ORR), time to progression (TTP), and progression-free survival (PFS), of which PFS has emerged as the most commonly used for assessing drug efficacy (86). In addition, patient-centred outcomes, usually patientreported outcomes, are used to assess clinical benefits from the patients' perspective.…”

Surrogacy analysis of intermediate end-points for overall survival in randomized controlled trials of rhabdomyosarcoma

“…In RCTs, EFS, defined as the primary end-point, has some advantages over OS, as it requires a small sample size, shorter follow-up period for assessment, and low cost 12,21 . Moreover, EFS is not generally affected by postprogression treatments.…”

“…It is possible that new diagnostic methods or anti-tumoral agents would dilute the surrogacy relationship in the future, even if the present surrogacy is reportedly strong 23 . Some reasons for the expectation of EFS as a surrogate end-point for OS are the social demand for early approval of new drugs and the theory that EFS is not only a surrogate end-point for OS but also makes positive contributions to the patients' quality of life 21 . Although many surrogate end-point analyses have evaluated the EFS surrogacy for OS, a true end-point in RCTs for various malignant tumors, there has been no such study for RMS.…”

Functional and structural brain abnormalities in substance use disorder: A multimodal meta‐analysis of neuroimaging studies

“…Meta-analysis is a potent approach for synthesizing inconsistent findings by accounting for between-study heterogeneities. 23 Several meta-analyses of neuroimaging studies indicated that it is practicable to pool various resting-state functional metrics together that can provide a more systematic assessment of brain dysfunction. [24][25][26] Of late, only one meta-analysis of resting-state functional…”

“…This inconsistency may be attributed to the different definitions of SUD, types of substances, duration of substance use, phase of addiction, and technical procedures. Meta‐analysis is a potent approach for synthesizing inconsistent findings by accounting for between‐study heterogeneities 23 . Several meta‐analyses of neuroimaging studies indicated that it is practicable to pool various resting‐state functional metrics together that can provide a more systematic assessment of brain dysfunction 24–26 .…”